Platelet indices in preeclampsia: comparative analysis with normotensive pregnant women.

IF 2.3 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-01-30 DOI:10.1080/17474086.2025.2458262

Hamza Tariq, Muhammad Hamza Khan, Fnu Poombal, Muhammad Saad Khan, Minahil Mateen Ahmad, Mehreen Khalid, Umera Saleem

{"title":"Platelet indices in preeclampsia: comparative analysis with normotensive pregnant women.","authors":"Hamza Tariq, Muhammad Hamza Khan, Fnu Poombal, Muhammad Saad Khan, Minahil Mateen Ahmad, Mehreen Khalid, Umera Saleem","doi":"10.1080/17474086.2025.2458262","DOIUrl":null,"url":null,"abstract":"Background: To compare platelet count (PC), mean platelet volume (MPV), and platelet distribution width (PDW) between women with preeclampsia (PE) and normotensive pregnant women, and evaluate their effectiveness as predictors of PE.Research design and methods: This cross-sectional study at Nishtar Hospital, Multan, included 141 women: 74 normotensive and 67 preeclamptic. Data was collected using an automated hematology analyzer and analyzed with SPSS version 26 and ROC curves.Results: Mean age was 27.45 ± 5.18 years for cases and 28.41 ± 5.28 years for controls (p = 0.280). Gestational age was lower in the preeclamptic group (31.97 ± 4.07 weeks) compared to controls (33.92 ± 3.30 weeks) (p = 0.002). Blood pressures were higher in preeclamptic women (p < 0.001). Platelet count was lower in preeclamptic women (183.42 ± 95.69) vs. controls (256.42 ± 77.98) (p < 0.001). MPV (10.98 ± 1.55 vs. 9.79 ± 1.59, p < 0.001) and PDW (16.82 ± 5.70vs. 14.20 ± 2.40, p < 0.001) were higher in preeclamptic women. ROC analysis showed PDW had an AUC of 0.73 and MPV an AUC of 0.71.Conclusions: PDW and MPV are significantly altered in preeclamptic women and can aid in early detection, potentially enhancing management.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"135-142"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2458262","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To compare platelet count (PC), mean platelet volume (MPV), and platelet distribution width (PDW) between women with preeclampsia (PE) and normotensive pregnant women, and evaluate their effectiveness as predictors of PE.

Research design and methods: This cross-sectional study at Nishtar Hospital, Multan, included 141 women: 74 normotensive and 67 preeclamptic. Data was collected using an automated hematology analyzer and analyzed with SPSS version 26 and ROC curves.

Results: Mean age was 27.45 ± 5.18 years for cases and 28.41 ± 5.28 years for controls (p = 0.280). Gestational age was lower in the preeclamptic group (31.97 ± 4.07 weeks) compared to controls (33.92 ± 3.30 weeks) (p = 0.002). Blood pressures were higher in preeclamptic women (p < 0.001). Platelet count was lower in preeclamptic women (183.42 ± 95.69) vs. controls (256.42 ± 77.98) (p < 0.001). MPV (10.98 ± 1.55 vs. 9.79 ± 1.59, p < 0.001) and PDW (16.82 ± 5.70vs. 14.20 ± 2.40, p < 0.001) were higher in preeclamptic women. ROC analysis showed PDW had an AUC of 0.73 and MPV an AUC of 0.71.

Conclusions: PDW and MPV are significantly altered in preeclamptic women and can aid in early detection, potentially enhancing management.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.